New CRC publication in Liver International

By |2024-08-08T09:57:55+02:0008.08.2024|

New CRC publication in Liver International: Using machine learning and big data to understand the gut liver axis Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one third of the population and can progress to much more severe states of liver damage influenced by the interplay of lifestyle, genes and environment. One [...]

New CRC publication in Advanced Science

By |2024-08-08T09:52:24+02:0009.07.2024|

New CRC publication in Advanced Science: Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease affecting more than one quarter of humankind. This study by Adrien Guillot, Frank [...]

Addressing the function of microbially conjugated bile salts in human bile

By |2024-08-06T12:04:33+02:0025.03.2024|

Publication in Hepatology Communications Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR   Bile salts are an important means of communication in the organ crosstalk between gut and liver. PhD student Ümran Ay, Frank Schaap, Steven Olde Damink [...]

Salmonella infection – non-professional efferocytosis contributes to barrier integrity in the neonate

By |2024-08-06T12:05:55+02:0007.02.2024|

Publication in the Journal of Experimental Medicine Salmonella infection: Non-professional efferocytosis contributes to barrier integrity in the neonate   The immune system and the intestinal barrier of neonates and adult organisms are fundamentally different. Therefore, infections with the enteropathogen Salmonella have a different course and outcome [...]

‘Gut–liver axis: barriers and functional circuits’ – Key findings and concepts of our CRC published in nature reviews gastrenterology & hepatology

By |2023-04-27T17:43:58+02:0027.04.2023|

nature reviews gastroenterology & hepatology:  'Gut-liver axis: barriers and functional circuits'   On behalf of our entire consortium, our spokesperson Oliver Pabst (B06, Q04), Mathias W. Hornef (B01, Q03), Frank Schaap (A07), Thomas Clavel (A05, Q02), Vuk Cerovic (B03) and Tony Bruns (B07) have summarised central [...]

‘Programmed and environmental determinants driving neonatal mucosal immune development’ – Publication in Immunity goes online on the first of May.

By |2023-04-27T17:41:45+02:0027.04.2023|

New CRC publication:  Programmed and environmental determinants driving neonatal mucosal immune development   Natalia Torow, one of our CRC1382 'Rising Stars' and PI Mathias Hornef (project B01) have published this review article in Immunity. 'In this paper we demonstrate that despite early microbial colonization the delayed [...]

Hepatology: Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression

By |2023-04-27T16:40:44+02:0027.04.2023|

New CRC publication:  Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression   PIs from external project B05 at Charité Berlin, Adrien Guillot as first author and Frank Tacke as last author, succeeded in publishing their results in the [...]

Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis

By |2023-01-06T13:20:52+01:0006.01.2023|

New CRC publication:  Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis   This publication in Clinical Gastroenterology and Hepatology is the result of intensive collaboration of scientists in our CRC. Scientists from 5 CRC projects participated in this study: [...]

“Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency”

By |2023-01-04T21:32:30+01:0022.11.2022|

New CRC publication:  Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency   Promising results on a phase 2 clinical study entitled "Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency" was recently published in The New England Journal of Medicine. Alpha1-antitrypsin deficiency is an inherited, proteotoxic disorder [...]

Go to Top